Overdiagnosis in lung cancer screening
- PMID: 33718051
- PMCID: PMC7947395
- DOI: 10.21037/tlcr-20-736
Overdiagnosis in lung cancer screening
Abstract
There have been hundreds of publications about overdiagnosis during the past decade describing concern regarding its potential for harms in lung cancer screening. However, the definition and frequency with which it occurs in screening trials remains unclear. This lack of clarity stems from its current definition which is not based on a clinical grounds but instead on an epidemiologic definition that depends on the cause of death. Thus, with the current definition an overdiagnosed cancer can only be diagnosed if the person does not die from the cancer, regardless of whether or not the cancer is aggressive or the treatment successful. Using a definition based on epidemiology rather than the clinical presentation is highly unusual. Furthermore, the frequency of overdiagnosis has also been a cause of great confusion. Prior to the results from the National Lung Screening trial (NLST), concerns were expressed that virtually all CT screen detected cancers would be overdiagnosed, yet the extended follow-up study of the National Lung Screening Trial shows that in essence there were virtually no overdiagnosis. Even more confusing is that it was previously suspected that there was a high rate of overdiagnosis when using chest radiographic screening and therefore as CT is a more sensitive imaging test and finds cancers even earlier, it would be presumed that the overdiagnosis rate for CT would be even be higher. A proposed change in the definition would focus more on the clinical manifestation of the cancer as to its aggressiveness as this can be diagnosed while the patient is alive. Using a definition that is based on clinical features, a cancer that manifests as a nonsolid nodule would be considered overdiagnosed if instead of being recognized as relatively indolent was instead thought to be an aggressive cancer. The concept of overtreatment arises if this nonaggressive cancer were treated aggressively.
Keywords: Overdiagnosis; lung cancer; screening harms.
2021 Translational Lung Cancer Research. All rights reserved.
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-736). The series “Implementation of CT-based screening of lung cancer” was commissioned by the editorial office without any funding or sponsorship. Dr. Yankelevitz reports other from Accumetra, other from GRAIL, outside the submitted work. In addition, Dr. Yankelevitz is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest including measurement of nodules. Some of these, which are owned by Cornell Research Foundation (CRF), are non-exclusively licensed to General Electric. As an inventor of these patents, I am entitled to a share of any compensation which CRF may receive from its commercialization of these patents. He is also an equity owner in Accumetra, a privately held technology company committed to improving the science and practice of image-based decision making. Dr Yankelevitz is also on the advisory board of GRAIL, Pfizer and AstraZeneca. Dr. Henschke is a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest which are owned by Cornell Research Foundation (CRF). Since 2009, Dr. Henschke does not accept any financial benefit from these patents including royalties and any other proceeds related to the patents or patent applications owned by CRF. Dr. Henschke is the President and serve on the board of the Early Diagnosis and Treatment Research Foundation. I receive no compensation from the Foundation. The Foundation is established to provide grants for projects, conferences, and public databases for research on early diagnosis and treatment of diseases. Recipients include, I-ELCAP, among others. The funding comes from a variety of sources including philanthropic donations, grants and contracts with agencies (federal and non-federal), imaging and pharmaceutical companies relating to image processing assessments. The various sources of funding exclude any funding from tobacco companies or tobacco-related sources. The authors have no other conflicts of interest to declare.
Similar articles
-
Do competing causes of mortality contribute to overdiagnosis in lung cancer screening?Lung Cancer. 2021 Mar;153:21-24. doi: 10.1016/j.lungcan.2020.12.031. Epub 2020 Dec 30. Lung Cancer. 2021. PMID: 33445120
-
Lung cancer screening overdiagnosis: reports of overdiagnosis in screening for lung cancer are grossly exaggerated.Acad Radiol. 2015 Aug;22(8):976-82. doi: 10.1016/j.acra.2014.10.011. Epub 2015 Mar 13. Acad Radiol. 2015. PMID: 25772581 Review.
-
Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials.Breathe (Sheff). 2020 Mar;16(1):200013. doi: 10.1183/20734735.0013-2020. Breathe (Sheff). 2020. PMID: 32194774 Free PMC article. Review.
-
What is overdiagnosis and why should we take it seriously in cancer screening?Public Health Res Pract. 2017 Jul 26;27(3):2731722. doi: 10.17061/phrp2731722. Public Health Res Pract. 2017. PMID: 28765855
-
Airflow Limitation and Histology Shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy.Am J Respir Crit Care Med. 2015 Nov 1;192(9):1060-7. doi: 10.1164/rccm.201505-0894OC. Am J Respir Crit Care Med. 2015. PMID: 26199983 Free PMC article.
Cited by
-
Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals.Eur J Med Res. 2023 Nov 4;28(1):478. doi: 10.1186/s40001-023-01462-3. Eur J Med Res. 2023. PMID: 37924162 Free PMC article.
-
The development and application of a novel precise health management model for pulmonary nodules population: a prospective cohort study.J Thorac Dis. 2025 Jun 30;17(6):4198-4209. doi: 10.21037/jtd-2025-906. Epub 2025 Jun 26. J Thorac Dis. 2025. PMID: 40688269 Free PMC article.
-
Curative intent therapy of stage I-III non-small cell lung cancer: a patient-centered precision approach to assess, measure, and interpret benefits and harms.J Thorac Dis. 2025 Jul 31;17(7):4473-4500. doi: 10.21037/jtd-2025-213. Epub 2025 Jul 29. J Thorac Dis. 2025. PMID: 40809242 Free PMC article.
-
The long-term course of subsolid nodules and predictors of interval growth on chest CT: a systematic review and meta-analysis.Eur Radiol. 2023 Mar;33(3):2075-2088. doi: 10.1007/s00330-022-09138-y. Epub 2022 Sep 22. Eur Radiol. 2023. PMID: 36136107 Free PMC article.
-
Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.Front Public Health. 2022 Sep 29;10:977550. doi: 10.3389/fpubh.2022.977550. eCollection 2022. Front Public Health. 2022. PMID: 36249202 Free PMC article.
References
-
- Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). Available online: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.... Accessed June 01/2020
-
- NCI Dictionary of Cancer Terms. Available online: www.cancer.gov/publications/dictionaries/cancer-terms/def/overdiagnosis. Accessed June 01/2020
-
- Miettinen OS. Epidemiological Research: Terms and Concepts. Dordrecht: Springer; 2011:20.
-
- Overdiagnosis. Available online: https://en.wikipedia.org/wiki/Overdiagnosis. Accessed June 01/2020.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous